Molecular epidemiology and clinical features of extended-spectrum beta-lactamase- or carbapenemase-producing Escherichia coli bacteremia in Japan

PloS One
Yuko KomatsuKeiichi Mikasa

Abstract

To identify risk factors and clinical outcomes in patients with bacteremia due to extended-spectrum beta-lactamase (ESBL) or carbapenemase-producing Escherichia coli, as well as to determine the prevalence and genetic background of such isolates. Case control study was performed with patients with E. coli bacteremia between January 2008 and May 2013 (n = 115) at a tertiary university hospital in Japan. Cases had ESBL-producing E. coli (ESBL-EC) whereas controls had non-ESBL-producing E. coli (non-ESBL-EC) isolates. A retrospective chart review was performed to identify risk factors and clinical outcomes. Isolates were characterized by antimicrobial susceptibility testing, polymerase chain reaction analysis for beta-lactamase genes, and multi-locus sequence typing. Of 115 unique cases of E. coli bacteremia, 30 (26.1%) were due to ESBL-EC and three (2.6%) were due to carbapenemase-producing E. coli. All three carbapenemase-producing E. coli isolates were IMP-6 and concurrently produced ESBL (ESBL/IMP-6-EC). ESBL-EC isolates showed multidrug resistance. Of the ESBL-EC isolates, CTX-M-27 was the most prevalent (33.3%), followed by CTX-M-14 (30%). Multi-locus sequence typing revealed that 19 (63.3%) isolates were ST131. The multivar...Continue Reading

References

Dec 1, 1996·Journal of Clinical Epidemiology·P PeduzziA R Feinstein
May 31, 2002·Journal of Clinical Microbiology·F Javier Pérez-Pérez, Nancy D Hanson
Nov 17, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J Rodríguez-BañoA Pascual
Feb 23, 2008·The Lancet Infectious Diseases·Johann D D Pitout, Kevin B Laupland
Jun 10, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Neil GuptaAlexander J Kallen
Nov 15, 2011·Diagnostic Microbiology and Infectious Disease·Norifumi ShigemotoMotoyuki Sugai
Feb 16, 2012·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Y MatsumuraS Ichiyama
Jun 6, 2012·Antimicrobial Agents and Chemotherapy·Hisakazu YanoMitsuo Kaku
Oct 5, 2013·Clinical Microbiology Reviews·Paul-Louis WoertherAntoine Andremont
Dec 18, 2013·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·E TacconelliUNKNOWN European Society of Clinical Microbiology
Jul 2, 2014·Clinical Microbiology Reviews·Marie-Hélène Nicolas-ChanoineJean-Yves Madec
Mar 19, 2015·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Ina WillemsenJan Kluytmans
Jul 21, 2015·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·B DenisJ-M Molina
Dec 27, 2015·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Akihiro NakamuraSeiji Kawano
Sep 28, 2016·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·James A McKinnellSusan S Huang
Oct 22, 2016·Emerging Infectious Diseases·Yasufumi MatsumuraSatoshi Ichiyama
Feb 6, 2017·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Yuki OhnoFumihiko Nakamura
Jul 16, 2017·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Yoshikazu IshiiHiroshi Kiyota

❮ Previous
Next ❯

Datasets Mentioned

BETA
KY964289

Software Mentioned

VITEK
Stata

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Protein Structures

Bacterial protein structures can expedite the development of novel antibiotics. Here is the latest research on bacterial proteins and the resolution of their structures.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.